By I. Abbas. Virginia Wesleyan College. 2018.
Preliminary evaluation of an immunochromatographic strip test for specific Treponema pallidum antibodies generic 40mg micardis. Syphilis: diagnosis generic micardis 20mg online, treatment and control 125 Questions and answres to questions 1 micardis 20mg with mastercard. In children born with recent congenital syphilis, a a) 12 hours clinical characteristic that may help in making diagno- b) 30 hours sis is: c) 7 days a) presence of cervical hypochromic lesions d) 14 days b) presence of chancre and secondary lesions c) rhinitis with mucous and bloody discharge 2. The only characteristic that is not found in hard d) presence of mixed chancre chancre is: a) clear basis 9. Which secondary syphilis lesions are important in d) absence of inoculation chancre terms of contagion? Tertiary syphilis lesions may appear after a long c) greater number of cases of resistant T. The dark field microscopy is a laboratory tool that d) more localized lesions should be used: a) if there are no fluorescent microscopes available 5. The false-negative results in non-treponemic tests, the so-called prozone effect, are due to: 6. The earliest neurological involvement of syphilis a) small number of treponemas in this stage is: b) low specificity of cardiolipin a) tabes dorsalis c) an excess of antibodies b) gommatous neurosyphilis d) very concentrated serum c) progressive general paralysis d) meningeal alterations 13. Today the treponemic tests are used primarily: a) to confirm the cases of syphilis 7. In which stage of pregnancy the embryo becomes b) in diagnosis of neurosyphilis infected? A pregnant woman was treated with erythromycin d) benzathine penicillin, two weekly doses of 2g/day for 15 days. Benzathine penicillin is the first line drug to treat should be treated for 30 days syphilis because of: b) penicillin is the only drug considered effective a) its low cost in pregnant women b) low incidence of side effects c) correct treatment, provided it is a case of c) its ability to cross the blood brain barrier primary syphilis d) it maintains therapeutic levels for longer periods d) it should not have been used for causing many side effects 20. The Jarish-Herxheimer reaction was described in other diseases caused by spirochetes, such as lep- 16. They are the unsung heroes of intracameral antibiotic prophylaxis of endophthalmitis following cataract surgery. Published by the European Society of Cataract and Refractive Surgeons, Temple House, Temple Road, Blackrock, Co Dublin, Ireland www. The visual loss and debilitation that occur unequivocally demonstrated a clinical beneft, with a in a large proportion of postoperative endophthalmitis fve-fold reduction in postoperative endophthalmitis rates cases can be severe and irreversible. Those most in need in patients who received a 1mg intracameral injection of of the operation are often those at greatest risk, such as cefuroxime at the close of cataract surgery1. In parallel, scientifc principles that underlie Although cataract surgery ranks among the most frequently microbial eradication in the atypical spaces of the eye have performed surgical procedures worldwide, data to defne been explored. The clinical beneft of scientifc principles that help us understand how bacteria this intervention seemed apparent. Other forms Exogenous endophthalmitis may present in an acute, of endophthalmitis may arise from endogenous sources virulent form, or a more chronic, late endophthalmitis. An endophthalmitis is related to the virulence and inoculum acceleration phase and, fnally, a destructive phase of the of infecting bacteria, as well as time to diagnosis and the infection develops. The acceleration phase follows primary infection of the The infectious process undergoes an initial incubation posterior segment and leads to infammation of the anterior phase which may be clinically unapparent, lasting at chamber and an immune response with macrophages and least 16-18 hours, during which a critical load of bacteria lymphocytes infltrating into the vitreous cavity within about proliferate and break down the aqueous barrier; this is 7 days. By 3 days after intraocular infection, pathogen- followed by fbrin exudation and cellular infltration by specifc antibodies can be detected; these help to eliminate neutrophilic granulocytes. The incubation phase varies microbes through opsonisation and phagocytosis within with the generation time of the infecting microbe, (eg: up about 10 days. Infammatory mediators, especially cytokines, further such as production of bacterial toxins. With common recruit leucocytes, which may add to destructive effects, microorganisms such as S. Surgical complications are endophthalmitis originate from environmental, a known risk factor for endophthalmitis, with higher climatic, surgical, and patient-specifc factors, among endophthalmitis rates cited where complications occur. In these Guidelines, we focus on prophylaxis Although the internal eye is protected to some degree of endophthalmitis after cataract surgery, and the by ocular barriers that confer an “immune privilege,” if microorganisms most commonly implicated in these compromised (e. The etiology of microorganisms infecting the eye during cataract surgery include the following: • patients presenting preoperatively with blepharitis and infammation or infection of the eyelids. It is • the patient’s own ocular surface fora [Speaker 1991, worthwhile mentioning that atopic patients and those Bannerman 1997]. A majority of contaminants during, with rosacea have altered conjunctival and lid bacterial and even after, surgery can be traced to the patient’s fora, with a higher preponderance of Staphylococcus own ocular surface fora. Patients with rosacea also exhibit an enhanced topical antibiotic drops in the early postoperative period systemic cell-mediated immunity to S. These patients • infection stemming from contaminated surgical should undergo treatment for their blepharitis prior to instruments, tubing or the surgical environment, cataract surgery with appropriate antibiotic therapy. Measures needed to assure the sterility of the surgical suite, airfow and instruments are briefy outlined here, but are too broad for comprehensive review, and the reader is referred to appropriate guidelines and practice standards. Because none of these factors endophthalmitis may vary with regions of the world, as can be precisely quantifed or identifed prior to cataract depicted in Table 6. Common microorganisms in postoperative endophthalmitis * Commonly cited prevalence may vary with geographic regions Table 2. In keeping with most reports, an important group of pathogens to be considered when Gram-positive microbes predominated, including species selecting a prophylactic antibiotic regimen. All groups received povidone-iodine 5% (Betadine) before surgery and were presented levofoxacin 0.
Standards of or olanzapine may be specifcally useful in individuals with bi- Practice Committee of the American Academy of Sleep Medi- polar disorder or severe anxiety disorders micardis 20 mg with visa. In for the psychological and behavioral treatment of insomnia: an some cases order micardis 20 mg free shipping, medications such as gabapentin or pregabalin may update purchase micardis 20 mg amex. Practice parameters with a longer-acting analgesic medication near bedtime may for the use of actigraphy in the assessment of sleep and sleep also be useful, although narcotic analgesics may disrupt sleep disorders: an update for 2007. Rules of evidence and clinical recommendations for bid insomnia may beneft from behavioral and psychological the management of patients. The burden of chronic insomnia on society: awaken- Combined Therapy for Insomnia ing insomnia management. Characteristics of insomnia in the United Hypnotic medications are effcacious as short-term treatment States: results of the 1991 National Sleep Foundation Survey. Epidemiology of insomnia: what we know and what sleep in a model of transient insomnia related to a novel sleep we still need to learn. Beneft-risk assessment of zaleplon in the miology of insomnia: prevalence, self-help treatments, consul- treatment of insomnia. Philadelphia: Elsevier mary insomnia: results of a polysomnographic double-blind con- Saunders, 2005:714-25. A review of the evidence for the effcacy and safe- Psychophysiological insomnia: the behavioural model and a neu- ty of trazodone in insomnia. Quantitative criteria on sleep physiology measures with major depression and insom- for insomnia. Vale- diagnostic criteria for insomnia: Report of an American Academy rian-hops combination and diphenhydramine for treating in- of Sleep Medicine Work Group. National Institutes of Health State nightly use of zolpidem in chronic insomnia: results of a large- of the Science Conference statement on Manifestations and Man- scale, double-blind, randomized, outpatient study. Certifed behavioral sleep clone over 6 months of nightly treatment: results of a randomized, medicine specialists. Rebound insomnia: dura- zolpidem for chronic insomnia: A meta-analysis of treatment ef- tion of use and individual differences. Eszopiclone co-admin- mals and patients with insomnia after abrupt and tapered discon- istered with fuoxetine in patients with insomnia coexisitng with tinuation. Trazodone for antide- chological treatment for insomnia in the management of long- pressant-associated insomnia Am J Psychiatry 1994;151:1069-72. Am J Psychiatry pharmacological therapies for late-life insomnia: a randomized 2004;161:332-42. Sedative hypnotics in cotherapy combined with stimulus control treatment in chronic older people with insomnia: meta-analysis of risks and benefts. A methodological approach is used to obtain information from the patient, usually starting with determining the patient’s chief complaint, also known as the reason for the healthcare visit, and then 2 chapter 1 / the patient interview delving further into an exploration of the patient’s specific complaint and problem. A comprehensive patient interview includes inquiring about the patient’s medical, medication, social, personal, and family history, as well as a thorough review of systems and possibly a physical examination. The medication history is the part of the patient interview that provides the pharmacist the opportunity to utilize his or her expertise by precisely collecting each component of the medication history (however, a medication history may also be collected independent of a comprehensive patient interview). The questions that you ask the patient, as well as the technique used, will enable you to learn exactly how, when, and why a patient takes each medication, as well as about any adverse reactions, allergies, or issues with medication cost the patient may have experienced. The approach to the patient interview and medication history will change based on the setting in which you are practicing. For example, if the setting is a community pharmacy and you are responding to a problem that may allow for self-care, your questions will be directed at meticulously characterizing the patient’s complaint and obtaining specific information that will influence your assessment and plan for the patient. However, if you are in a hospital, the focus of the interview may need to be modified based on the patient’s condition and the particular unit or department in which he or she is being cared for so that the patient’s needs may be met. Regardless of the setting, your goal during the interview will be to provide patient-centered care; this can be accomplished by combining your pharmaco- therapeutic knowledge with a solid foundation of excellent communication and patient-interviewing skills. Excelling in these communication skills is a learned technique that takes time and practice to master. Once these skills are employed in practice, the relationship that is developed with the patient is often stronger, allowing for the patient to have increased confidence and trust in your role as a healthcare provider. The purpose of this chapter is to describe the various components of the compre- hensive health history and to provide an overview of the skills and techniques required when communicating with the patient. This chapter will focus on the best practices to follow when collecting information from the patient. Although communicating with a patient may seem like a simple task, it actually takes communication skills 3 practice and knowledge to communicate with the patient in a manner that encour- ages respect for the healthcare provider and that enables the pharmacist to obtain an accurate and complete history. Some practitioners are able to naturally commu- nicate with patients more effectively, whereas others have difficulty communicat- ing with patients due to a variety of reasons, including their personality, comfort level, and confidence. However, regardless of one’s natural abilities, communica- tion skills and questioning techniques, especially when it comes to communicating with patients, are learned and take time to develop. This chapter examines the most pertinent skills required to conduct a comprehensive medication history. These skills and questioning techniques include: • Active listening • Empathy • Building rapport • Open-ended questions • Closed-ended questions • Leading questions • Silence • “Why” questions • Nonverbal communication cues active Listening The first communication skill to be mastered is listening, specifically active listen- ing. Listening is defined as hearing what is being said, whereas active listening is a dynamic process that includes both hearing what is being said as well as processing and interpreting the words that are spoken (and/or unspoken) to understand the complete message that is being delivered. Whereas listening is a passive process, active listening requires the listener to consciously choose to give the patient atten- tion and concentration that is free of distractions and interruptions, both external and internal. External distractions include ringing telephones, flickering computer screens, and other infringing per- sonal and/or other duties. These external distractions can be avoided by interacting with your patient in a place that is free of such distractions. Internal distractions occur for two major reasons: (1) many matters, unre- lated to the patient in front of you, may occupy your mind and (2) it is difficult 4 chapter 1 / the patient interview to perceive what the patient is saying without tainting his or her message with your personal judgment. The first reason can be addressed by making a conscious effort to concentrate solely on your interaction with the patient.
Apart from occasionally taking some aspirin he has not used any medication in the past year cheap 80mg micardis. Auscultation reveals a murmur over the right carotid artery and the right femoral artery generic micardis 40 mg with visa. You are fairly sure of the diagnosis cheap 80mg micardis otc, angina pectoris, and explain the nature of this disease to him. You explain that the attacks are usually self-limiting, but that they can also be stopped by drugs. You consider prescribing ®1 Cordacor , because you have read something about it in an advertisement. Later at home you think about the case, and about your problem in finding the right drug for the patient. Angina pectoris is a common condition, and you decide to choose a P-drug to help you in the treatment of future cases. Many of these are rather similar to the steps you went through in treating the patient with cough in Chapter 1. In Chapter 1 you have chosen a drug for an individual patient; in this chapter you will choose a drug of first choice for a common condition, without a specific patient in mind. It can be subdivided into classic angina pectoris or variant angina pectoris; it may also be divided into stable and unstable. You could specify the diagnosis of patient 2 as stable angina pectoris, caused by a partial (arteriosclerotic) occlusion of the coronary arteries. Step ii: Specify the therapeutic objective Angina pectoris can be prevented and treated, and preventive measures can be very effective. As angina pectoris is caused by an imbalance in oxygen need and supply in the cardiac muscle, either oxygen supply should be increased or oxygen demand reduced. It is difficult to increase the oxygen supply in the case of a sclerotic obstruction in the coronary artery, as a stenosis cannot be dilated with drugs. This leaves only one other approach: to reduce the oxygen need of the cardiac muscle. Since it is a life-threatening situation this should be achieved as soon as possible. This therapeutic objective can be achieved in four ways: by decreasing the preload, the contractility, the heart rate or the afterload of the cardiac muscle. Step iii: Make an inventory of effective groups of drugs 2 If you do not know enough about pathophysiology of the disease or of the pharmacological sites of action, you need to update your knowledge. You could start by reviewing your pharmacology notes or textbook; for this example you should probably also read a few paragraphs on angina pectoris in a medical textbook. In this case the drugs must decrease preload, contractility, frequency and/or afterload. There are three groups with such an effect: nitrates, beta-blockers and calcium channel blockers. Table 2: Sites of action for drug groups used in angina pectoris Preload Contractility Frequency Afterload Nitrates ++ - - ++ Beta-blockers + ++ ++ ++ Calcium channel blockers + ++ ++ ++ Step iv: Choose an effective group according to criteria The pharmacological action of these three groups needs further comparison. During this process, three other criteria should be used: safety, suitability and cost of treatment. Safety All drug groups have side effects, most of which are a direct consequence of the working mechanism of the drug. In the three groups, the side effects are more or less equally serious, although at normal dosages few severe side effects are to be expected. Suitability This is usually linked to an individual patient and so not considered when you make your list of P-drugs. When a patient suffers an attack of angina pectoris there is usually nobody around to administer a drug by injection, so the patient should be able to administer the drug alone. Thus, the dosage form should be one that can be handled by the patient and should guarantee a rapid effect. Table 3 also lists the available dosage forms with a rapid effect in the three drug groups. All groups contain drugs that are available as injectables, but nitrates are also available in 24 Chapter 3 Example of selecting a P-drug: angina pectoris sublingual forms (sublingual tablets and oromucosal sprays). These are equally effective and easy to handle, and therefore have an advantage in terms of practical administration by the patient. Cost of treatment Prices differ between countries, and are more linked to individual drug products than to drug groups. In Table 4, indicative prices for drugs within the group of nitrates, as given in the British National Formulary of March 1994, have been included for the sake of the example. As you can see from the table, there are considerable price differences within the group. You should check whether in your country nitrates are more expensive than beta-blockers or calcium channel blockers, in which case they may lose their advantage. Step v: Choose a P-drug 26 Chapter 3 Example of selecting a P-drug: angina pectoris Choose an active substance and a dosage form Not all nitrates can be used in acute attacks, as some are meant for prophylactic treatment. In general, three active substances are available for the treatment of an acute attack: glyceryl trinitrate (nitroglycerin), isosorbide mononitrate and isosorbide dinitrate (Table 4). In some countries an oromucosal spray of glyceryl trinitrate is available as well. The advantage of such sprays is that they can be kept longer; but they are more expensive than tablets. There is no evidence of a difference in efficacy and safety between the three active substances in this group.
Diabetologia 2013 cheap micardis 40mg line;56: Patient Education laces with three or four eyes per side buy cheap micardis 40mg on line, pad- 457–466 All patients with diabetes and particu- ded tongue order micardis 80 mg free shipping, quality lightweight materials, 10. Albuminuria changes and and sufﬁcient size to accommodate a cush- (history of ulcer or amputation, defor- cardiovascular and renal outcomes in type 1 di- ioned insole. Clin J Am Soc footwear can help reduce the risk of future Nephrol 2016;11:1969–1977 should be provided general education foot ulcers in high-risk patients (106,108). Effect of inten- about risk factors and appropriate man- Most diabetic foot infections are poly- sive diabetes treatment on albuminuria in agement (107). Patients at risk should type 1 diabetes: long-term follow-up of the Di- microbial, with aerobic gram-positive understand the implications of foot de- abetes Control and Complications Trial and cocci. Wounds without evidence of soft- nol 2014;2:793–800 care; and the importance of foot moni- tissue or bone infection do not require 12. N Engl J therapy can be narrowly targeted at substitute other sensory modalities Med 2011;365:2366–2376 gram-positive cocci in many patients 13. Effect of intensive blood-glucose control unbreakable mirror) for surveillance of for infection with antibiotic-resistant with metformin on complications in overweight early foot problems. Lan- organisms or with chronic, previously The selection of appropriate footwear cet 1998;352:854–865 treated, or severe infections require and footwear behaviors at home should 14. Patients’ understand- be referred to specialized care centers phonylureas or insulin compared with conven- ing of these issues and their physical (109). Patients with cet 1998;352:837–853 or vascular surgeon, or rehabilitation spe- visual difﬁculties, physical constraints pre- 15. Intensivebloodglucose con- venting movement, or cognitive problems of individuals with diabetes (109). N Engl J Med 2008;358:2560– dition of the foot and to institute appro- 2572 References priate responses will need other people, 1. Treatment cal practice guideline for the evaluation and man- Lancet 2010;376:419–430 People with neuropathy or evidence of 17. Kidney Int of blood-pressure lowering and glucose control in increased plantar pressures (e. Clin Biochem shoes or athletic shoes that cushion the Renal hemodynamic effect of sodium-glucose Rev 2016;37:17–26 feet and redistribute pressure. Ann Intern Med 2003;139:137–147 pagliﬂozin and progression of kidney disease in 5. Canagliﬂozinslowspro- commercial therapeutic footwear, will re- the United States. Re- Liraglutide and cardiovascular outcomes in type 2 hot, swollen foot or ankle, and Charcot nal insufﬁciency in the absence of albuminuria and diabetes. N Engl J pies on retinopathy progression in type 2 diabe- ney Dis 2015;66:441–449 Med 2004;351:1952–1961 tes. Effects of treatment approach, and glycated haemoglobin of diabetic nephropathy in patients with type 2 di- prior intensive insulin therapy and risk factors concentration on the risk of severe hypoglycae- abetes. N Engl J Med 2001;345:870–878 on patient-reported visual function outcomes in mia: post hoc epidemiological analysis of the 40. Diabetes mellitus as a compelling indication Epidemiology of Diabetes Interventions and Compli- 24. N Engl J Med 2011;364:907–917 blockers in patients with type 2 diabetes and comes in patients with type 2 diabetes. N Engl J Med 2009;361:40–51 retinopathy: a position statement by the American term beneﬁtsof intensiveglucose control for pre- 43. The Diabetes Control and Complications Diabetes Care 2016;39:694–700 high risk for vascular events. Am J Kidney Dis 2012;60:850–886 ﬁnerenone on albuminuria in patients with di- 2000;23:1084–1091 28. Department of Health and Human Ser- doxazosin to determine the optimal treatment 1319 vices. Screening for presence or absence ings regarding use of the diabetes medicine cet 2015;386:2059–2068 of diabetic retinopathy: a meta-analysis. Accessed 15 October 2016 heart failure and diabetes mellitus and/or chronic for diabetic retinopathy. Cana- Med 2010;362:1575–1585 Early referral to specialist nephrology services dian Ophthalmological Society evidence-based 32. Tight for preventing the progression to end-stage kid- clinical practice guidelines for the management blood pressure control and risk of macrovascu- ney disease. Oph- Effects of losartan on renal and cardiovascular tes Care 1995;18:258–268 thalmology 1996;103:1815–1819 outcomes in patients with type 2 diabetes and 50. Am J Kidney Dis 1998;31: 20-year prospective study of childbearing and inhibition on diabetic nephropathy. N Engl J 947–953 incidence of diabetes in young women, control- Med 1993;329:1456–1462 51. Diabetes 2007;56:2990–2996 antagonist irbesartan in patients with nephropa- Studies. Preliminary report on effects of photo- 345:851–860 effects of medical management on the progres- coagulation therapy. Photocoagulation for Suppl 2012;2:337 Ophthalmology 2014;121:2443–2451 diabetic macular edema: Early Treatment Dia- 37. Diabetes Control and Complications Trial Re- betic Retinopathy Study report number 1. The effect of intensive treatment of Ophthalmol 1985;103:1796–1806 diovascularand microvascularoutcomes in peo- diabetes on the development and progression 69. N Engl J Med 1993;329: uating ranibizumab plus prompt or deferred la- 355:253–259 977–986 ser or triamcinolone plus prompt laser for S98 Microvascular Complications and Foot Care Diabetes Care Volume 40, Supplement 1, January 2017 diabetic macular edema.
The chapter continues with a review of the rigorous research on the effectiveness and population impact of prevention policies generic 40 mg micardis mastercard, most of which are associated with alcohol misuse generic 80mg micardis fast delivery, as there is limited scientifc literature on policy interventions for other drugs cheap micardis 20mg without prescription. Detailed reviews of these programs and policies are in Appendix B - Evidence-Based Prevention Programs and Policies. The chapter then describes how communities can build the capacity to implement effective programs and policies community wide to prevent substance use and related harms, and concludes with research recommendations. These predictors show much consistency across gender, race and ethnicity, and income. These programs and policies are effective at different stages of the lifespan, from infancy to adulthood, suggesting that it is never too early and never too late to prevent substance misuse and related problems. To build effective, sustainable prevention across age groups and populations, communities should build cross-sector community coalitions which assess and prioritize local levels of risk and protective factors and substance misuse problems and select and implement evidence-based interventions matched to local priorities. This shift was a result of effective public health interventions, such as improved sanitation and immunizations that reduced the rate of infectious diseases, as well as increased rates of unhealthy behaviors and lifestyles, including smoking, poor nutrition, physical inactivity, and substance misuse. In fact, behavioral health problems such as substance use, violence, risky driving, mental health problems, and risky sexual activity are now the leading causes of death for those aged 15 to 24. Although people generally start using and misusing substances during adolescence, misuse can begin at any age and can continue to be a problem across the lifespan. For example, the highest prevalence of past month binge drinking and marijuana use occurs at ages 21 and 20, respectively. Other drugs follow similar trajectories, although their use typically begins at a later age. Also, early initiation, substance misuse, and substance use disorders are associated with a variety of negative consequences, including deteriorating relationships, poor school performance, loss of employment, diminished mental health, and increases in sickness and death (e. Preventing or reducing early substance use initiation, substance misuse, and the harms related to misuse requires the implementation of effective programs and policies that address substance misuse across the lifespan. The prevention science reviewed in this chapter demonstrates that effective prevention programs and policies exist, and if implemented well, they can markedly reduce substance misuse and related threats to the health of the population. For example, studies have found that many schools and communities are using prevention programs and strategies that have little or no evidence of effectiveness. Factors that increase the infuence the likelihood that a person will use a substance and likelihood of beginning substance use, whether they will develop a substance use disorder. Factors that physiological changes that occur over the course of directly decrease the likelihood of substance use and behavioral health development or to factors in a person’s environment—for problems or reduce the impact of risk example, biological transitions such as puberty or social factors on behavioral health problems. These factors can be infuenced by programs and policies at multiple levels, including the federal, state, community, family, school, and individual levels. Therefore, programs and policies addressing those common or overlapping predictors of problems have the potential to simultaneously prevent substance misuse as well as other undesired outcomes. However, research has shown that binge drinking is more common among individuals in higher income households as compared to lower income households. Despite the similarities in many identifed risk factors across groups, it is important to examine whether there are subpopulation differences in the exposure of groups to risk factors. Early and persistent problem Emotional distress, aggressiveness, and 48,49 behavior “diffcult” temperaments in adolescents. Favorable attitudes toward Positive feelings towards alcohol or drug 51,52 substance use use, low perception of risk. Family Poor management practices, including parents’ failure to set clear expectations Family management problems 57-60 for children’s behavior, failure to supervise (monitoring, rewards, etc. Confict between parents or between Family confict61-63 parents and children, including abuse or neglect. Parental attitudes that are favorable Favorable parental attitudes64,65 to drug use and parental approval of drinking and drug use. Persistent, progressive, and generalized Family history of substance 66,67 substance use, misuse, and use disorders misuse by family members. Community 30,72 Low alcohol sales tax, happy hour Low cost of alcohol specials, and other price discounting. High number of alcohol outlets in a High availability of substances73,74 defned geographical area or per a sector of the population. Community reinforcement of norms suggesting alcohol and drug use is Community laws and norms 75,76 acceptable for youth, including low tax favorable to substance use rates on alcohol or tobacco or community beer tasting events. Living in neighborhoods with high population density, lack of natural Community disorganization82,83 surveillance of public places, physical deterioration, and high rates of adult crime. A parent’s low socioeconomic status, Low socioeconomic status84,85 as measured through a combination of education, income, and occupation. Family, School, and Community Developmentally appropriate Opportunities for positive social 93,94 opportunities to be meaningfully involved involvement with the family, school, or community. Parents, teachers, peers and community members providing recognition for Recognition for positive behavior51 effort and accomplishments to motivate individuals to engage in positive behaviors in the future. Attachment and commitment to, and Bonding95-97 positive communication with, family, schools, and communities. Married or living with a partner in a Marriage or committed relationship98 committed relationship who does not misuse alcohol or drugs. Family, school, and community norms Healthy beliefs and standards for that communicate clear and consistent 51,99 behavior expectations about not misusing alcohol and drugs. Note: These tables present some of the key risk and protective factors related to adolescent and young adult substance initiation and misuse. Communities must choose from these three types of preventive interventions, but research has not yet been able to suggest an optimal mix. Communities may think it is best to direct services only to those with the highest risk and lowest protection or to those already misusing substances.
Cost-lowering stragies used by medicare beneficiaries who exceed drug beneficaps and have a gap in drug coverage buy micardis 40 mg low price. Potilaiden nakemyksia kohonneen verenpaineen hoidosta � hoitomyontyvyyttako paranta- malla tuloksiin? Changes in the reasons for requiring out-of-hours medical care from a centralized primary care centre afr changing to a lissysm cheap micardis 80 mg free shipping. Prospective study on la consequences of subclical non-compliance with immunosuppressive therapy in renal transplanpatients micardis 40mg sale. Social networks as predictors of ishemic heardisease, cancer, stroke and hypernsion: incidence, survival and mortality. Whahas been learned from electronic monitoring of compliance with antihypernsive medications? Self-initiad modification of hypernsion treatmenin response to perceived problems. A randomized controlled trial of an information booklefor hypernsive patients in general practice. Facts and fiction of poor compliance as a cause of inadequa blood pressure control: a sysmatic review. Effecof aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Tutkimuksemme tavoitena on selvittaa verenpainetaudin laakehoitoon liittyvia ongelmia laakkeen kayttajan nakokulmasta. Tutkimuksen tuloksia on tarkoitus hyodyntaa verenpainehoidon suunnitlussa ja laakitykseen liittyvassa neuvonnassa. Toivomme idan ystavallisesti vastaavan oheisiin kysymyksiin tarkasti ja huolellisesti seka palauttamaan kyselyn oheisessa kirjekuoressa (postimaksu on jo maksettu) mahdollisimman pian, mutta kuinkin viimeistaan kahden viikon kuluessa. Kaikki antamanne tiedokasillaan ehdottoman vaitiolovelvollisuuden pohjalta ja vastauksianne kaytaan vain tutkimuskayttoon. Oppaan ovakirjoittaneeSydantautiliiton asiantuntijalaakari Jyrki Olkinuora ja dosentti Timo Klaukka. Mikali haluaosallistua arvontaan tayttakaa oheinen erillinen arvontalomake ja palauttakaa myos se vastauskuoressa. Arvontalomakkeerollaan vastauslomakkeista valittomasti niiden saavuttua, eika henkilotietoja liita tutkimustietoihin missaan vaiheessa. Jos illa on kysyttavaa tutkimuksesta, voisoittaa professori Hannes Enlundille puh: 971-162 500 tai proviisoriopiskelija Erkki Jokisalolle puh 981-311 2019. Onko rveydentilanne nykyisin mieles- 2 kerran paivassa tai useammin tanne yleensa 3 muutaman kerran viikossa 4 muutaman kerran kuukaudessa 1 hyva 5 harvemmin 2 melko hyva 6 en kayta verenpainemittaria 3 kohtalainen 4 melko huono 5 huono 12. Ovatko kayttamanne verenpainelaakkeeaiheuttaneeille epamiellyttavia tunmuksia tai haittavaikutuksia? Haittavaikutus (laakkeen nimi) erittain epa- kohtalaisen hieman jokseenkin miellyttava epamiellyttava epamiellyttava harmiton 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 16. Onko idan ollupakko luopua jostakin mukavista asioista (esimerkiksi harrastuk- sista) verenpainetautinne vuoksi? Jos kaytaverenpainelaakkeita oman 3 usein mielenne mukaisesti, niin mitka seuraavista ovamielestanne tarkeimmasyysiihen 20. Aiheuttaako verenpainelaakkeen oton 6 laake jai uusimatta, jon en kayta sita sovittaminen paivarytmiin hankaluuksia 7 laakkeiden jatkuva nauttiminen ei ole (tyon, matkuslun tai muun sellaisen syyn 8 muu syy, mika? Ovatko verenpainelaakkeiden aiheut- tamakustannukseille taloudellisesti 1 ei 2 joskus 1 suuri rasi 3 usein 2 kohtalainen rasi 3 vahainen rasi 4 taysin merkitykseton rasi 29. Oletko mielestanne saanutarpeeksi tietoa verenpainelaakkeiden En Kylla En osaa sanoa annostuksesta. Osallistumme valtakunnalliseen Verenpainepotilaan hoito rveyskeskuksessa 1996 - 97 -tutkimukseen, johon meidan lisaksemme osallistuu 29 muuta rveyskeskusta eri puolilta Suomea. Jotta tutkimus meidan rveyskeskuksessamme onnistuisi hyvin, pyydan ita tayttamaan nama kyselylomakkeehuolellisesti. Tuodessanne kyselyn osa I:n hoitajan vastaanotolle, voiyhdessa taydentaa mahdollisesti puuttuvatiedoja hoitaja tayttaa lomakkeen viimeiselle sivulle laboratorio- yms. Sen sijaan rveyskeskuksemme saa paikkakuntamme kaikkien tutkittavien potilaiden vastausn keskiarvot. Naiden tulosn perusella voimme kiinnittaa huomiota rveyskeskuksemme verenpaineen hoidossa mahdollisesti ilmeneviin puutisiin ja parantaa nain potilaitmme hoidon laatua. Omalaboratorio- ja seurantakayntinne tuloksesaahoitajalta ja hoitavalta laakariltanne. Tullessanne hoitajan vastaanotolle, ottakaa mukaan kaikkien laakarin maaraamien ja nykyisin kayttamienne laakkeiden resepti(tai laakepurkit, mikali eloyda resepjanne). Tutkimuksen vastuulaakari (leima) Arvoisa potilas Verenpaineen hyva hoito on ensiarvoisen tarkeaa torjuttaessa sydan- ja verisuonitauja, erityisesti aivohalvauksia ja sepelvaltimotautia (sydaninfarkja). Tassa tutkimuksessa pyrimme saamaan mahdollisimman seikkaperaisen kuvan verenpaineen hoidon toutumisesta Suomessa. Antamanne tiedovoivaolla ratkaisevia pyrittaessa parantamaan verenpainepotilaan hoitoa maassamme. Luonnollisesti myos yliopistossa noudataan vastauksienne suhen ehdotonta vaitiolovelvollisuutta. VastausohjeeRengastakaa vastausvaihtoehdoista vain yksi, ellei kysymyksen ohjeissa ole muuta mainittu, esimerkiksi Hoitaako verenpainettanne paaasiassa 1 rveyskeskuslaakari 2 tyorveyslaakari rveyskeskuksessa 3 muu tyorveyslaakari 4 yksityislaakari 5 en ole laakarin hoidossa verenpaineeni vuoksi Avoimissa kysymyksissa kirjoittakaa vastaus sille varattuun tilaan. Esimerkiksi Ovatko talla hetkella kaytossanne olevaverenpainelaakkeeaiheuttaneeille mitaan haittavaikutuksia 1 ei 2 kylla, mika laake ja millaisia haittavaikutuksia?
Research has been able to recognize several factors associad with non-compliance purchase micardis 40mg overnight delivery, buour possibilities to improve compliance are very limid generic 80 mg micardis visa. We know thanon-compliance is associad with poor treatmenoutcomes in many diseases trusted micardis 20mg, including hypernsion. The high discontinuation ras of antihypernsive medications, aleasin the early stages of treatment, have been found to be more than alarming. On the other hand, hypernsion research has been able to recognize several factors associad with poor blood pressures, butoday, only a minority of hypernsive patients reach the targelevels of blood pressure in Finland as well as in many other countries. To describe the prevalence of differenperceived problems and attitudes in the treatmenof hypernsion. To evalua the association of perceived problems and attitudes with non- compliance with antihypernsive drug therapy. To evalua the association of perceived problems and attitudes as well as non- compliance with the control of blood pressure with antihypernsive drug therapy. To be eligible to participa in the study, the patients had to fulfil the following criria: born in the year 1921 or lar, buying antihypernsive medication for himself/herself and entitled to receive special reimbursemenfor antihypernsive medication under the national sickness insurance program. Of the patients invid to participa (n = 971), 105 refused and 866 agreed and received a questionnaire to be compled ahome (Figure 1). Of the respondents, 54 were excluded from the analyses due to missing data on aleasone variable. Men Women Total Characristic n % n % n % Age < 50 years 47 24 41 18 88 21 50 � 64 years 104 52 98 43 202 47 65 � 75 years 48 24 90 39 138 32 Education primary 75 38 126 55 201 47 secondary 97 49 87 38 184 43 academic 27 14 16 7 43 10 Years of treatmen< 5 45 23 48 21 93 22 5 � 9 57 29 47 21 104 24 10 � 19 56 28 64 28 120 28 > 20 41 21 70 31 111 26 Number of antihypernsive drugs 1 96 48 100 44 196 46 2 75 38 103 45 178 42 3 � 5 28 14 26 11 54 13 4. These findings motivad the initiation of a new study on the treatmensituation and problems in hypernsion care in 1996-1997. Thirty health centres ouof the a total of 250 health centres in Finland were randomly selecd by stratified sampling as representative of the basic population in rms of size and geographical location. Twenty-six health centres with a total of 255 general practitioners agreed to participa in the study. During one week in November 1996, these general practitioners identified all of the hypernsive patients who visid them (n = 2. During the following three 48 months, public health nurses sento these patients two questionnaires and an invitation to a health examination. Athe health examination a trained public health nurse checked any missing data in the firsquestionnaire. The second questionnaire, which contained confidential data on the local doctors, nurses and health care sysm, was handed to the nurse in a closed envelope to be mailed to the university. Eighty-four per cenof the patients had aleasthree blood pressure readings from the year 1996 and the early parof 1997. In these measurements, the patients had had mean systolic and diastolic blood pressures 2. The prevalence of patient-perceived problems analyses were also carried ouon the medically untread population, which consisd of 220 patients, 90 (40. If the systolic and diastolic blood pressure values had been calculad based on the smaller of the two recorded readings, the respective values would have been 149. Men Women Total Characristic n % n % n % Age < 55 years 144 23 186 20 330 21 55 � 64 years 183 30 224 24 407 26 65 � 74 years 217 35 308 33 525 34 > 75 years 71 12 228 24 299 19 Education a lower 431 71 739 79 1170 75 b higher 180 29 200 21 380 25 Duration of hypernsion < 5 years 166 27 228 24 394 25 5 � 9 years 134 22 186 20 320 21 > 10 years 312 51 525 56 837 54 Number of antihypernsive drugs 1 331 54 462 49 793 51 2 223 36 375 40 598 38 3 � 5 59 10 105 11 164 11 a basic school, junior secondary school, primary school or parts of these curricula b academic education, occupational school, vocational school, senior secondary school Pharmacy-based study population Primary health care based study population 971 Were invid to participa 2219 Were invid to participa 105 Refused to participa 437 Did noparticipa 866 Agreed to participa 1782 Participad 384 Did noreturn the 1 Was excluded due to questionnaire missing data 482 Returned the questionnaire 1781 Study population with adequaly filled questionnaires 54 Were excluded due to 220 Medically untread missing data population 428 Final study population 1561 Final study population Figure 1. The two questionnaires included a total of 82 questions aboulifestyle, health care sysm, medication, blood pressure measurements and the patient�s experiences relad to the treatmenof hypernsion. These areas were identified from the lirature as being critical for good hypernsion care. The original questions were answered on a five- poinLikerscale (1 = absoluly agree, 2 = somewhaagree, 3 = somewhadisagree, 4 = absoluly disagree, 5 = does noconcern me) or a three-poinscale (14 questions: 1 = correct, 2 = nocorrect, 3 = does noconcern me). Using factor analysis with varimax rotation on these 82 questions, 21 factors were identified (eigenvalue of > 1. Four factors, including aspects of nonpharmacological treatmenof hypernsion, such as weighreduction (three factors) and use of salt, were excluded. The questions in the factors were dichotomized as 1 (those with a problem: absoluly agree, somewhaagree, and correct) and 0 (those withoua problem: somewhadisagree, absoluly disagree, nocorrect, does noconcern me, and missing data). On the basis of reliability and inrnal validity analyses, some questions and four of the factors were excluded. One factor was splibecause of its poor inrnal validity, and a total of 14 problem areas covered by 45 questions were thus identified. Experiences concerning the symptoms of hypernsion and adverse 51 drug effects were elicid by asking the patienwhether his/her hypernsion (or drug treatment) had caused any symptoms (adverse effects). We assessed the perceived difficulties to be hypernsive by asking whether the patienfeliwas difficulto be a patienwith hypernsion. Perceived memory problems were assessed by asking whether iwas difficulto remember to take antihypernsive drugs. The patients were also asked whether they had had to give up any pleasanactivities due to hypernsion. Finally, they were asked whether hypernsion or drug taking had inrfered with their daily routines and hobbies. The number of problems was defined as the sum of positive responses to the above seven questions. The patients were then classified into one of four cagories: having no problems, one, two and three or more problems. Non-compliance Self-initiad modification of dosage instructions was assessed by asking whether the patienhad ever tried to manage with less antihypernsive drugs than those prescribed. Those selecting "ofn" or "sometimes" were classified as modifiers and those answering "no" as nonmodifiers.